The Importance Of Assessing And Mitigating Immunogenicity Potential

Source: Lonza

By Noel Smith, Ph.D., and Yvette Stallwood, Ph.D.


While the reasons for clinical failure vary, a large portion is due to issues with safety and efficacy. Unwanted immunogenicity can have severe consequences for patients, this is why understanding the potential immunogenicity and immunotoxicity of your candidate is a regulatory requirement to support your first-in-human program. As the biopharmaceutical developer, it is your responsibility to ensure you have adequately assessed the possibility of your drug candidate eliciting an unwanted immune response. Unfortunately, immunogenicity assessment is also an area where "standard" in vivo toxicology assessments might lack clinical relevance. To overcome this challenge, read our E-Book and get an expert view on the challenges of early immunosafety assessment and available risk mitigation strategies.

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online